Transcatheter aortic valve implantation (TAVI) is a safe and effective alternative to surgical aortic valve replacement in patients with severe aortic stenosis who are considered inoperable or at high surgical risk.
What are the recent updates in patient selection, procedural approaches, and outcomes for transcatheter aortic valve implantation in patients with severe aortic stenosis?
This review summarizes the current state of TAVI, highlighting its safety in high-risk/inoperable patients and anticipating expansion to broader patient populations.
Aortic valve replacement is the mainstay of treatment for symptomatic severe aortic stenosis. In this setting, the rapidly evolving field of transcatheter aortic valve implantation (TAVI) is currently considered a safe alternative to surgical aortic valve replacement in patients with severe aortic stenosis who are considered inoperable or at high surgical risk. This review will focus on recent changes in the field of TAVI, describing patient selection, valve types, procedural approaches, short and long-term outcomes, and complications. The rapid evolution of TAVI procedures supported by solid evidence will, in the near future, probably extend the indications to a wider portion of patients with aortic stenosis.
Biagioni et al. (Thu,) conducted a review in Severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve implantation (TAVI) is a safe and effective alternative to surgical aortic valve replacement in patients with severe aortic stenosis who are considered inoperable or at high surgical risk.